FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386537783> ?p ?o ?g. }

• W4386537783 endingPage "ii62" @default.
• W4386537783 startingPage "ii62" @default.
• W4386537783 abstract "Abstract BACKGROUND Approximately half of late-stage melanoma patients develop brain metastases (BM), once metastasized to the brain, survival is generally measured in months. Current treatments, although increasingly effective, are not sufficient for this patient group, necessitating development of new therapeutic options. Drugs targeting BM specifically are a scarcity. To broaden therapeutic options, drug repurposing, i.e. novel uses of drugs already approved for other medical conditions, may prove to be a valuable asset. By design, antipsychotics effectively cross an intact blood-brain barrier. Interestingly, although carrying an increased burden of comorbidity, the schizophrenic population has a similar incidence of cancer when compared to the normal population. Hypotheses regarding the antitumor effect of antipsychotics have therefore been postulated along with several other theories that seek to explain these seemingly contradictory incidence rates. We currently present preliminary data showing that clozapine, a second-generation antipsychotic, effectively inhibits growth of human melanoma brain metastasis (MBM) cell lines in vitro. Objective: To explore the potential of antipsychotics in treating MBM. METHODS Cell cultures including H1, H2, H3 MBM cell lines, as well as normal human astrocytes (NHA) were selected for our experiments. Monolayer, 3D, and IncuCyte viability experiments were performed to determine IC50 doses. FBRO, fetal rat brain organoids were used to study clozapine’s effect on the normal brain environment. Cell migration was measured by scratch wound assays. Apoptosis was studied by flow cytometry. Colony formation assays were performed using 2D clonogenic assays. A protein array was used to find signaling proteins potentially affected by clozapine, which where verified by western blots. RESULTS A viability screening using 6 different neuroleptics showed that clozapine was most effective in inhibiting MBM cell viability, with a favorable therapeutic window to astrocytes. Doses significantly above MBM IC50 doses did not affect viability of brain organoids. MBM cells exhibited a dose-dependent inhibition of cell proliferation, migration, and clonogenic formation. Flow cytometry demonstrated that apoptosis was a major mechanism of cytotoxicity. The protein array showed that CCL3, IL8 and VEGF were downstream targets of clozapine. These results were confirmed by western blots. A partnership with the Dept. of Chemistry (UiB) has resulted in the development and testing of several novel clozapine derivates to reduce therapeutic doses and hopefully minimize potential side effects. CONCLUSION Clozapine shows proof of concept in treating BM with antipsychotics and should be explored further as an adjuvant treatment for melanoma patients at risk of developing brain metastasis." @default.
• W4386537783 created "2023-09-09" @default.
• W4386537783 creator A5007358546 @default.
• W4386537783 creator A5018730565 @default.
• W4386537783 creator A5041043163 @default.
• W4386537783 creator A5058821119 @default.
• W4386537783 creator A5062037396 @default.
• W4386537783 creator A5073255936 @default.
• W4386537783 creator A5076532155 @default.
• W4386537783 creator A5077636380 @default.
• W4386537783 creator A5092774495 @default.
• W4386537783 date "2023-09-01" @default.
• W4386537783 modified "2023-10-17" @default.
• W4386537783 title "P10.03.A ANTIPSYCHOTICS TO TREAT BRAIN TUMORS: DRUG REPURPOSING TO BYPASS THE BLOOD BRAIN BARRIER" @default.
• W4386537783 doi "https://doi.org/10.1093/neuonc/noad137.201" @default.
• W4386537783 hasPublicationYear "2023" @default.
• W4386537783 type Work @default.
• W4386537783 citedByCount "0" @default.
• W4386537783 crossrefType "journal-article" @default.
• W4386537783 hasAuthorship W4386537783A5007358546 @default.
• W4386537783 hasAuthorship W4386537783A5018730565 @default.
• W4386537783 hasAuthorship W4386537783A5041043163 @default.
• W4386537783 hasAuthorship W4386537783A5058821119 @default.
• W4386537783 hasAuthorship W4386537783A5062037396 @default.
• W4386537783 hasAuthorship W4386537783A5073255936 @default.
• W4386537783 hasAuthorship W4386537783A5076532155 @default.
• W4386537783 hasAuthorship W4386537783A5077636380 @default.
• W4386537783 hasAuthorship W4386537783A5092774495 @default.
• W4386537783 hasBestOaLocation W43865377831 @default.
• W4386537783 hasConcept C103637391 @default.
• W4386537783 hasConcept C117262875 @default.
• W4386537783 hasConcept C118552586 @default.
• W4386537783 hasConcept C121608353 @default.
• W4386537783 hasConcept C126322002 @default.
• W4386537783 hasConcept C143998085 @default.
• W4386537783 hasConcept C190283241 @default.
• W4386537783 hasConcept C2776412080 @default.
• W4386537783 hasConcept C2778087573 @default.
• W4386537783 hasConcept C2779438470 @default.
• W4386537783 hasConcept C2780035454 @default.
• W4386537783 hasConcept C2780864610 @default.
• W4386537783 hasConcept C2908647359 @default.
• W4386537783 hasConcept C55493867 @default.
• W4386537783 hasConcept C71924100 @default.
• W4386537783 hasConcept C86803240 @default.
• W4386537783 hasConcept C98274493 @default.
• W4386537783 hasConcept C99454951 @default.
• W4386537783 hasConceptScore W4386537783C103637391 @default.
• W4386537783 hasConceptScore W4386537783C117262875 @default.
• W4386537783 hasConceptScore W4386537783C118552586 @default.
• W4386537783 hasConceptScore W4386537783C121608353 @default.
• W4386537783 hasConceptScore W4386537783C126322002 @default.
• W4386537783 hasConceptScore W4386537783C143998085 @default.
• W4386537783 hasConceptScore W4386537783C190283241 @default.
• W4386537783 hasConceptScore W4386537783C2776412080 @default.
• W4386537783 hasConceptScore W4386537783C2778087573 @default.
• W4386537783 hasConceptScore W4386537783C2779438470 @default.
• W4386537783 hasConceptScore W4386537783C2780035454 @default.
• W4386537783 hasConceptScore W4386537783C2780864610 @default.
• W4386537783 hasConceptScore W4386537783C2908647359 @default.
• W4386537783 hasConceptScore W4386537783C55493867 @default.
• W4386537783 hasConceptScore W4386537783C71924100 @default.
• W4386537783 hasConceptScore W4386537783C86803240 @default.
• W4386537783 hasConceptScore W4386537783C98274493 @default.
• W4386537783 hasConceptScore W4386537783C99454951 @default.
• W4386537783 hasIssue "Supplement_2" @default.
• W4386537783 hasLocation W43865377831 @default.
• W4386537783 hasOpenAccess W4386537783 @default.
• W4386537783 hasPrimaryLocation W43865377831 @default.
• W4386537783 hasRelatedWork W122825480 @default.
• W4386537783 hasRelatedWork W1980001478 @default.
• W4386537783 hasRelatedWork W1980952315 @default.
• W4386537783 hasRelatedWork W2058372121 @default.
• W4386537783 hasRelatedWork W2144557577 @default.
• W4386537783 hasRelatedWork W2351779880 @default.
• W4386537783 hasRelatedWork W2369295560 @default.
• W4386537783 hasRelatedWork W3022989435 @default.
• W4386537783 hasRelatedWork W4292428568 @default.
• W4386537783 hasRelatedWork W4386121943 @default.
• W4386537783 hasVolume "25" @default.
• W4386537783 isParatext "false" @default.
• W4386537783 isRetracted "false" @default.
• W4386537783 workType "article" @default.